EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

7 am 8 am (60 mins)

Main agenda

Continental breakfast

7 am 7 am (0 mins)

Main agenda

Registration Opens

10 am 6 pm (480 mins)

Main agenda

Exhibition opens

10 am 6 pm (480 mins)

Main agenda

One-to-one Meetings

9 am 9:55 am (55 mins)

Main agenda

The vital role of gene and cell therapy translational centers: Opportunities for value-generating partnerships

How can companies, investors, disease research foundations and patient organizations collaborate more effectively with researchers and investigators at the leading gene and cell therapy translational centers? What models are leading to clinical successes?

10 am 10:20 am (20 mins)

Main agenda

How are potential breakthroughs in gene and cell therapy challenging conventional assumptions about the evolving healthcare marketplace?

How will the landscape change and who will be involved as more diseases have the potential to be treated or even cured with the advances in this field? What does it take to develop, manufacture, and commercialize these life-changing treatments?

10:20 am 11:25 am (65 mins)

Main agenda

Pharma’s take on cell and gene therapies

What are pharma's strategic perspectives on cell and gene therapies? How is pharma investing in this space? What does pharma view as the major therapeutic opportunities for cell and gene therapies?

11:30 am 12:25 pm (55 mins)

Main agenda

Cell-based immunotherapies for cancer treatment

What's in the pipeline of engineered T cells and other cell-based approaches that have the industry buzzing? How will these therapies will be delivered and what is the potential for combinations immunomodulatory treatments?

  • Speaker Isabelle Rivière - Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center

12:30 pm 1:30 pm (60 mins)

Main agenda

Networking Luncheon

1:30 pm 3 pm (90 mins)

Main agenda

Industry Presentations

3 pm 3:15 pm (15 mins)

Main agenda

Networking Break

3:20 pm 4:04 pm (44 mins)

Main agenda

Best practices for partnering with disease foundations and patient groups

The roundtable will highlight case studies of companies that have successfully partnered with disease foundations and those linked to patient advocacy groups. How are companies, disease foundations, and patient advocacy groups working together effectively? What is the nature of these partnerships? What works and what can they be improved?

  • Speaker Ron Bartek - President, Friedreich’s Ataxia Research Alliance, Board of Directors, National Organization for Rare Disorders
  • Speaker Tim Miller - President and CEO, Abeona Therapeutics

4:05 pm 4:55 pm (50 mins)

Main agenda

Are cell and gene therapies ready for commercialization?

What are the “taking it to the next level” strategies being used by companies that are close to commercialization and what does the commercial ecosystem look like? In addition to the therapeutic developer, who are the other key participants? What are their roles and are they willing or able to share any of the risk?

5 pm 6 pm (60 mins)

Main agenda

Fireside Chat

6 pm 7:30 pm (90 mins)

Main agenda

Reception at the Ronald Reagan Building